Assembly Biosciences Stock Price, News & Analysis (NASDAQ:ASMB)

$56.82 -1.06 (-1.83 %)
(As of 02/20/2018 01:01 PM ET)
Previous Close$56.82
Today's Range$56.25 - $58.68
52-Week Range$18.60 - $58.68
Volume188,400 shs
Average Volume155,141 shs
Market Capitalization$988.54 million
P/E Ratio-19.13
Dividend YieldN/A
Beta0.77

About Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences logoAssembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.

Receive ASMB News and Ratings via Email

Sign-up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty & Advanced Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNASDAQ:ASMB
CUSIP92282210
Phone+1-212-5544388

Debt

Debt-to-Equity RatioN/A
Current Ratio5.62%
Quick Ratio5.62%

Price-To-Earnings

Trailing P/E Ratio-19.1313131313131
Forward P/E Ratio-17.65
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.64 per share
Price / Book12.25

Profitability

Trailing EPS($2.97)
Net Income$-44,260,000.00
Net MarginsN/A
Return on Equity-81.70%
Return on Assets-43.94%

Miscellaneous

Employees69
Outstanding Shares20,130,000

Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions

What is Assembly Biosciences' stock symbol?

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences Inc (NASDAQ:ASMB) announced its quarterly earnings data on Monday, November, 17th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by $0.84. View Assembly Biosciences' Earnings History.

Where is Assembly Biosciences' stock going? Where will Assembly Biosciences' stock price be in 2018?

3 brokers have issued 12 month price targets for Assembly Biosciences' stock. Their predictions range from $35.00 to $50.00. On average, they expect Assembly Biosciences' stock price to reach $40.00 in the next twelve months. View Analyst Ratings for Assembly Biosciences.

Who are some of Assembly Biosciences' key competitors?

Who are Assembly Biosciences' key executives?

Assembly Biosciences' management team includes the folowing people:

  • Derek A. Small, President, Chief Executive Officer, Director (Age 39)
  • David J. Barrett CPA, , Chief Financial Officer, Chief Operating Officer (Age 39)
  • Thomas E. Rollins, Chief Development Officer
  • William R Ringo JR, Independent Non-Executive Chairman of the Board (Age 70)
  • Alan James Lewis Ph.D., Director (Age 71)
  • Susan Mahony Ph.D., Director
  • Anthony E. Altig, Independent Director (Age 61)
  • Mark Auerbach CPA, , Independent Director (Age 77)

Who owns Assembly Biosciences stock?

Assembly Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (10.53%), BlackRock Inc. (5.36%), Perceptive Advisors LLC (2.67%), Rock Springs Capital Management LP (2.24%), Farallon Capital Management LLC (1.24%) and Emerald Advisers Inc. PA (0.95%). View Institutional Ownership Trends for Assembly Biosciences.

Who sold Assembly Biosciences stock? Who is selling Assembly Biosciences stock?

Assembly Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Lyon Street Capital LLC, Deutsche Bank AG, Wells Fargo & Company MN, Metropolitan Life Insurance Co. NY, Goldman Sachs Group Inc., Strs Ohio, Rhumbline Advisers and JGP Global Gestao de Recursos Ltda.. View Insider Buying and Selling for Assembly Biosciences.

Who bought Assembly Biosciences stock? Who is buying Assembly Biosciences stock?

Assembly Biosciences' stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Farallon Capital Management LLC, Emerald Advisers Inc. PA, BlackRock Inc., Armistice Capital LLC, Perceptive Advisors LLC, Bogle Investment Management L P DE and Rock Springs Capital Management LP. View Insider Buying and Selling for Assembly Biosciences.

How do I buy Assembly Biosciences stock?

Shares of Assembly Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Assembly Biosciences' stock price today?

One share of Assembly Biosciences stock can currently be purchased for approximately $56.82.

How big of a company is Assembly Biosciences?

Assembly Biosciences has a market capitalization of $988.54 million. The biopharmaceutical company earns $-44,260,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis. Assembly Biosciences employs 69 workers across the globe.

How can I contact Assembly Biosciences?

Assembly Biosciences' mailing address is 11711 N Meridian St Ste 310, CARMEL, IN 46032-4549, United States. The biopharmaceutical company can be reached via phone at +1-212-5544388 or via email at [email protected]


MarketBeat Community Rating for Assembly Biosciences (ASMB)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  209
MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Assembly Biosciences (NASDAQ:ASMB) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.673.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $40.00$40.00$42.50$35.00
Price Target Upside: 10.93% downside10.93% downside31.09% upside36.19% upside

Assembly Biosciences (NASDAQ:ASMB) Consensus Price Target History

Price Target History for Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences (NASDAQ:ASMB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/5/2018B. RileyInitiated CoverageNeutral -> Neutral$35.00HighView Rating Details
11/8/2017Jefferies GroupInitiated CoverageBuy$50.00N/AView Rating Details
9/17/2017Chardan CapitalReiterated RatingBuyMediumView Rating Details
8/19/2016William BlairInitiated CoverageMarket Perform -> OutperformN/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Assembly Biosciences (NASDAQ:ASMB) Earnings History and Estimates Chart

Earnings by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences (NASDAQ ASMB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017Q3 2017($0.88)($0.71)$1.25 million$2.66 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.78)$2.36 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.03)($0.81)$12.50 million$0.68 millionViewN/AView Earnings Details
3/2/2017Q4 2016($0.67)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.67)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.59)ViewN/AView Earnings Details
5/10/2016Q1 2016($0.64)ViewN/AView Earnings Details
3/11/2016Q4 2015($0.45)ViewN/AView Earnings Details
11/9/2015Q3 2015($0.38)ViewN/AView Earnings Details
8/13/2015Q2 2015($0.41)ViewN/AView Earnings Details
5/8/2015Q1 2015($0.64)ViewN/AView Earnings Details
3/16/2015Q4 2014($0.38)ViewN/AView Earnings Details
11/17/2014Q3 2014($0.49)($1.33)ViewN/AView Earnings Details
8/14/2014Q2 2014($0.55)($0.52)ViewN/AView Earnings Details
4/2/2014($0.28)($0.29)ViewN/AView Earnings Details
8/9/2013Q2 2013($1.10)($1.20)ViewN/AView Earnings Details
5/10/2013Q1 2013($1.10)($1.10)ViewN/AView Earnings Details
11/13/2012Q3 2012($1.80)($2.05)ViewN/AView Earnings Details
8/9/2012Q2 2012($2.80)($2.95)ViewN/AView Earnings Details
5/9/2012Q1 2012($2.65)($3.30)ViewN/AView Earnings Details
11/14/2011Q3 2011($2.45)($2.50)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Assembly Biosciences (NASDAQ:ASMB) Earnings Estimates

2018 EPS Consensus Estimate: ($3.19)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.96)($0.96)($0.96)
Q2 20181($0.71)($0.71)($0.71)
Q3 20181($0.74)($0.74)($0.74)
Q4 20181($0.78)($0.78)($0.78)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Assembly Biosciences (NASDAQ:ASMB)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Assembly Biosciences (NASDAQ ASMB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.60%
Institutional Ownership Percentage: 66.34%
Insider Trades by Quarter for Assembly Biosciences (NASDAQ:ASMB)
Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences (NASDAQ ASMB) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/1/2018William R RingoDirectorSell1,000$46.86$46,860.00View SEC Filing  
1/2/2018William R RingoDirectorSell1,000$45.04$45,040.00View SEC Filing  
12/1/2017William R RingoDirectorSell1,000$49.37$49,370.0020,465View SEC Filing  
11/1/2017William R RingoDirectorSell1,000$29.55$29,550.00View SEC Filing  
10/16/2017William R RingoDirectorSell1,000$33.70$33,700.00View SEC Filing  
2/11/2016Derek A. SmallCEOBuy10,000$5.53$55,300.00634,391View SEC Filing  
5/27/2014Russell H EllisonCEOBuy13,000$0.92$11,960.00View SEC Filing  
5/23/2014David Jonathan BarrettCFOBuy6,980$0.86$6,002.80View SEC Filing  
5/23/2014Russell H EllisonCEOBuy20,000$0.91$18,200.00View SEC Filing  
5/21/2014Russell EllisonCEOBuy10,000$0.87$8,700.0025,000View SEC Filing  
5/20/2014David Jonathan BarrettCFOBuy40,000$0.88$35,200.0040,000View SEC Filing  
2/5/2013Russell H EllisonCEOBuy15,000$2.55$38,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Assembly Biosciences (NASDAQ ASMB) News Headlines

Source:
DateHeadline
 Brokerages Anticipate Assembly Biosciences Inc (ASMB) Will Announce Quarterly Sales of $1.68 Million Brokerages Anticipate Assembly Biosciences Inc (ASMB) Will Announce Quarterly Sales of $1.68 Million
www.americanbankingnews.com - February 12 at 5:28 AM
Investor Expectations to Drive Momentum within Regal Beloit, Kaiser Aluminum, AngioDynamics, Mulesoft, Assembly Biosciences, and Woodward — Discovering Underlying Factors of InfluenceInvestor Expectations to Drive Momentum within Regal Beloit, Kaiser Aluminum, AngioDynamics, Mulesoft, Assembly Biosciences, and Woodward — Discovering Underlying Factors of Influence
finance.yahoo.com - February 6 at 8:30 AM
Assembly Biosciences (ASMB) Stock Rating Upgraded by ValuEngineAssembly Biosciences (ASMB) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - February 3 at 2:36 PM
Assembly Biosciences Inc (ASMB) Director Sells $46,860.00 in StockAssembly Biosciences Inc (ASMB) Director Sells $46,860.00 in Stock
www.americanbankingnews.com - February 2 at 10:02 PM
Assembly Biosciences Inc (ASMB) Given Consensus Rating of "Hold" by AnalystsAssembly Biosciences Inc (ASMB) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - January 30 at 9:39 AM
Zacks: Brokerages Expect Assembly Biosciences Inc (ASMB) Will Post Earnings of -$0.79 Per ShareZacks: Brokerages Expect Assembly Biosciences Inc (ASMB) Will Post Earnings of -$0.79 Per Share
www.americanbankingnews.com - January 24 at 1:36 PM
Commit To Purchase Assembly Biosciences At $40, Earn 41.3% Annualized Using OptionsCommit To Purchase Assembly Biosciences At $40, Earn 41.3% Annualized Using Options
www.nasdaq.com - January 24 at 8:51 AM
Assembly Biosciences (ASMB) Downgraded by Zacks Investment Research to HoldAssembly Biosciences (ASMB) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - January 15 at 5:50 PM
Assembly Biosciences Inc (ASMB) Expected to Announce Quarterly Sales of $1.68 MillionAssembly Biosciences Inc (ASMB) Expected to Announce Quarterly Sales of $1.68 Million
www.americanbankingnews.com - January 9 at 10:36 AM
BidaskClub Lowers Assembly Biosciences (ASMB) to HoldBidaskClub Lowers Assembly Biosciences (ASMB) to Hold
www.americanbankingnews.com - January 6 at 8:52 PM
Assembly Biosciences Inc (ASMB) Given Average Recommendation of "Buy" by BrokeragesAssembly Biosciences Inc (ASMB) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 5 at 10:18 AM
Assembly Biosciences (ASMB) Coverage Initiated at B. RileyAssembly Biosciences (ASMB) Coverage Initiated at B. Riley
www.americanbankingnews.com - January 5 at 8:54 AM
Assembly Biosciences to Present at the J.P. Morgan Healthcare ConferenceAssembly Biosciences to Present at the J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 11:12 AM
William R. Ringo Sells 1,000 Shares of Assembly Biosciences Inc (ASMB) StockWilliam R. Ringo Sells 1,000 Shares of Assembly Biosciences Inc (ASMB) Stock
www.americanbankingnews.com - January 3 at 7:54 PM
Assembly Biosciences Target of Unusually Large Options Trading (ASMB)Assembly Biosciences Target of Unusually Large Options Trading (ASMB)
www.americanbankingnews.com - December 31 at 2:40 AM
Zacks: Assembly Biosciences Inc (ASMB) Given Average Rating of "Strong Buy" by BrokeragesZacks: Assembly Biosciences Inc (ASMB) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - December 28 at 9:06 PM
 Brokerages Expect Assembly Biosciences Inc (ASMB) Will Announce Quarterly Sales of $1.68 Million Brokerages Expect Assembly Biosciences Inc (ASMB) Will Announce Quarterly Sales of $1.68 Million
www.americanbankingnews.com - December 24 at 7:52 PM
Assembly Biosciences Appoints Sue Mahony, PhD to Board of DirectorsAssembly Biosciences Appoints Sue Mahony, PhD to Board of Directors
finance.yahoo.com - December 19 at 11:22 AM
Zacks: Brokerages Set $42.50 Price Target for Assembly Biosciences Inc (ASMB)Zacks: Brokerages Set $42.50 Price Target for Assembly Biosciences Inc (ASMB)
www.americanbankingnews.com - December 13 at 4:14 PM
Assembly Biosciences (ASMB) Downgraded by BidaskClubAssembly Biosciences (ASMB) Downgraded by BidaskClub
www.americanbankingnews.com - December 10 at 5:14 PM
Assembly Biosciences (ASMB) Downgraded to Sell at ValuEngineAssembly Biosciences (ASMB) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - December 9 at 5:46 PM
Financial Contrast: Eagle Pharmaceuticals (EGRX) vs. Assembly Biosciences (ASMB)Financial Contrast: Eagle Pharmaceuticals (EGRX) vs. Assembly Biosciences (ASMB)
www.americanbankingnews.com - December 7 at 9:24 AM
Assembly Biosciences Inc (ASMB) Director William R. Ringo Sells 1,000 SharesAssembly Biosciences Inc (ASMB) Director William R. Ringo Sells 1,000 Shares
www.americanbankingnews.com - December 4 at 7:02 PM
Assembly Biosciences Inc (ASMB) Expected to Post Earnings of -$0.79 Per ShareAssembly Biosciences Inc (ASMB) Expected to Post Earnings of -$0.79 Per Share
www.americanbankingnews.com - December 4 at 3:26 AM
 Assembly Biosciences, Inc. (ASMB) Receives Consensus Recommendation of "Strong Buy" from Analysts Assembly Biosciences, Inc. (ASMB) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - November 27 at 1:36 AM
$1.68 Million in Sales Expected for Assembly Biosciences, Inc. (ASMB) This Quarter$1.68 Million in Sales Expected for Assembly Biosciences, Inc. (ASMB) This Quarter
www.americanbankingnews.com - November 17 at 6:52 AM
Assembly Biosciences, Inc. (ASMB) Lifted to Buy at Zacks Investment ResearchAssembly Biosciences, Inc. (ASMB) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - November 15 at 5:06 PM
William Blair Analysts Increase Earnings Estimates for Assembly Biosciences, Inc. (ASMB)William Blair Analysts Increase Earnings Estimates for Assembly Biosciences, Inc. (ASMB)
www.americanbankingnews.com - November 15 at 7:32 AM
Equities Analysts Issue Forecasts for Assembly Biosciences, Inc.s Q1 2018 Earnings (ASMB)Equities Analysts Issue Forecasts for Assembly Biosciences, Inc.'s Q1 2018 Earnings (ASMB)
www.americanbankingnews.com - November 14 at 9:35 AM
Brokerages Anticipate Assembly Biosciences, Inc. (ASMB) to Post ($0.93) Earnings Per ShareBrokerages Anticipate Assembly Biosciences, Inc. (ASMB) to Post ($0.93) Earnings Per Share
www.americanbankingnews.com - November 12 at 1:10 AM
Assembly Biosciences, Inc. (ASMB) to Post FY2017 Earnings of ($3.49) Per Share, Jefferies Group ForecastsAssembly Biosciences, Inc. (ASMB) to Post FY2017 Earnings of ($3.49) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - November 10 at 8:34 AM
Assembly Biosciences to Present at the Jefferies London Healthcare ConferenceAssembly Biosciences to Present at the Jefferies London Healthcare Conference
finance.yahoo.com - November 8 at 6:23 PM
Zacks: Assembly Biosciences, Inc. (ASMB) Given $25.50 Consensus Target Price by AnalystsZacks: Assembly Biosciences, Inc. (ASMB) Given $25.50 Consensus Target Price by Analysts
www.americanbankingnews.com - November 7 at 5:32 AM
Assembly Biosciences, Inc. (ASMB) Director William R. Ringo Sells 1,000 SharesAssembly Biosciences, Inc. (ASMB) Director William R. Ringo Sells 1,000 Shares
www.americanbankingnews.com - November 3 at 9:44 PM
Assembly Biosciences Announces Pricing of $60 Million Offering of Common StockAssembly Biosciences Announces Pricing of $60 Million Offering of Common Stock
finance.yahoo.com - November 2 at 2:46 AM
Assembly Biosciences Announces Proposed Underwritten Offering of Common StockAssembly Biosciences Announces Proposed Underwritten Offering of Common Stock
finance.yahoo.com - November 1 at 4:42 PM
Assembly Biosciences (ASMB) vs. Repligen Corporation (RGEN) Financial SurveyAssembly Biosciences (ASMB) vs. Repligen Corporation (RGEN) Financial Survey
www.americanbankingnews.com - October 27 at 11:26 PM
Assembly Biosciences, Inc. – Value Analysis (NASDAQ:ASMB) : October 26, 2017Assembly Biosciences, Inc. – Value Analysis (NASDAQ:ASMB) : October 26, 2017
finance.yahoo.com - October 26 at 4:06 PM
Assembly Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : ASMB-US : October 25, 2017Assembly Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : ASMB-US : October 25, 2017
finance.yahoo.com - October 25 at 5:13 PM
William R. Ringo Sells 1,000 Shares of Assembly Biosciences, Inc. (ASMB) StockWilliam R. Ringo Sells 1,000 Shares of Assembly Biosciences, Inc. (ASMB) Stock
www.americanbankingnews.com - October 17 at 8:18 PM
Commit To Purchase Assembly Biosciences At $25, Earn 15.7% Annualized Using OptionsCommit To Purchase Assembly Biosciences At $25, Earn 15.7% Annualized Using Options
www.thestreet.com - October 13 at 9:12 PM
Check-Cap (CHEK) & Assembly Biosciences (ASMB) Head-To-Head ComparisonCheck-Cap (CHEK) & Assembly Biosciences (ASMB) Head-To-Head Comparison
www.americanbankingnews.com - October 12 at 2:26 AM
Assembly Biosciences, Inc. (ASMB) Upgraded by Zacks Investment Research to HoldAssembly Biosciences, Inc. (ASMB) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - October 10 at 5:46 PM
Reviewing Assembly Biosciences (ASMB) & Its CompetitorsReviewing Assembly Biosciences (ASMB) & Its Competitors
www.americanbankingnews.com - October 4 at 2:10 AM
Assembly Biosciences Selects Next-Generation CpAM Candidate for Advancement into Clinical DevelopmentAssembly Biosciences Selects Next-Generation CpAM Candidate for Advancement into Clinical Development
finance.yahoo.com - October 2 at 3:59 PM
Assembly Biosciences Announces 2017 AASLD PresentationsAssembly Biosciences Announces 2017 AASLD Presentations
finance.yahoo.com - October 2 at 3:59 PM
Analyzing Assembly Biosciences (ASMB) and Its CompetitorsAnalyzing Assembly Biosciences (ASMB) and Its Competitors
www.americanbankingnews.com - October 1 at 4:38 PM
Head-To-Head Contrast: Assembly Biosciences (ASMB) & Its PeersHead-To-Head Contrast: Assembly Biosciences (ASMB) & Its Peers
www.americanbankingnews.com - October 1 at 6:24 AM
Assembly Biosciences (ASMB) Presents At Cambridge Healthtech Institutes 15th Annual Discovery On Target - SlideshowAssembly Biosciences (ASMB) Presents At Cambridge Healthtech Institute's 15th Annual Discovery On Target - Slideshow
seekingalpha.com - September 28 at 4:33 PM
Analyzing Assembly Biosciences (ASMB) & Its RivalsAnalyzing Assembly Biosciences (ASMB) & Its Rivals
www.americanbankingnews.com - September 28 at 8:28 AM

SEC Filings

Assembly Biosciences (NASDAQ:ASMB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Assembly Biosciences (NASDAQ:ASMB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Assembly Biosciences (NASDAQ ASMB) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.